Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

XS-03 i kombination med Folfox eller Folfiri og bevacizumab til behandling af metastatiske kolorektale kræftpatienter med RAS-mutation (XS-03-II201)

En åben mærket multicenter fase IB/II klinisk undersøgelse: Formålet at værdsætte effektiviteten og sikkerheden for XS-03-komination med FOLFOX eller FOLFIRI og bevacizumab hos metastatiske kolorektal kræftpatienter med RAS-mutation

XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

102

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Beijing, Kina
        • Beijing Cancer Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

  1. Voluntarily participate in the clinical trial and sign the informed consent form.
  2. Age ≥18 and ≤ 75 years. No gender restrictions.
  3. Patients with histologically and/or cytologically confirmed metastatic colorectal cancer who are not suitable for surgical treatment.
  4. Advanced or metastatic colorectal cancer: Stage Ib patients must have received at least one prior systemic therapy; Stage II patients have no prior systemic therapy. For patients with previously neoadjuvant/adjuvant therapy, disease progression must occur no less than 6 months after the end of therapy to be eligible for inclusion.
  5. Documentation of RAS mutation. The previously gene test report issued by qualified testing institution is acceptable. BRAF status is not restricted.
  6. Consent to provide tumor tissue samples and peripheral blood for biomarker analysis.
  7. Has measurable extracranial lesion according to RECIST v1.1 criteria, defined as at least one lesion that has not received radiotherapy. For previously radiotherapy lesion, there must be imaging evidence of progression after radiotherapy.
  8. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
  9. Expected life expectancy ≥ 6 months.
  10. The patient has adequate hepatic, renal and bone marrow function.
  11. For a woman of child-bearing potential must have a negative serum pregnancy test within 7 days prior to enrollment. Woman of child-bearing potential and fertile men must agree to use adequate contraception for the duration of study participation and for 6 months after the last dose.

Exclusion Criteria

  1. Patients with known high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) primary or metastatic colorectal cancer and suitable for immune checkpoint inhibitor treatment assessed by investigators.

  2. Previously received bevacizumab and its biosimilar therapy. (Only for phase II)

  3. Central nervous system metastases which are symptomatic or require therapy.

  4. Imaging shows major blood vessel invasion (such as the aorta, pulmonary artery, pulmonary vein, vena cava, etc.).

  5. Adverse events and/or complications that caused by previous antitumor therapy have not recovered to baseline level or ≤ CTCAE grade 1.

    Baseline level or ≤ Grade 1. However, any grade of alopecia, pigmentation, or ≤ Grade 2 peripheral sensory neuropathy, or other conditions assessed by the investigator as having become chronic and not affecting the safety of the study medication are allowed for inclusion.

  6. With a history of other malignancies within 5 years or with other malignancies currently prior to screening, except colorectal cancer. Exception: curatively treated early-stage malignancies (in situ carcinoma or stage I tumors), such as adequately treated basal cell or squamous cell skin cancer or in situ cancer of the cervix.

  7. Patients have a significant risk of bleeding.

  8. Patients have a significant risk of thrombus.

  9. Patients have severe cardiovascular disease, including but not limited to: Ischemic heart disease within the past 6 months prior to screening; coronary artery disease post-surgery or stent implantation within 6 months; New York Heart Association (NYHA) functional classification ≥ Class II within 6 months prior to screening; or known left ventricular insufficiency (LVEF <50%);transient ischemic attack or cerebrovascular accident within 6 months prior to screening; uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) despite standard treatment, or history of hypertensive crisis or hypertensive encephalopathy;severe arrhythmia requiring clinical intervention; any other cardiovascular disease that researchers regard the patient unsuitable for participation in the study.

  10. Patients with a significantly increased risk of QTc prolongation.

  11. Patients unable to swallow drugs or have severe diseases that significantly affect drug absorption.

  12. Patients have one of the following viral active infections: active hepatitis B or C; human immunodeficiency virus (HIV) infection; active syphilis

  13. During screening, the presence of interstitial lung disease, interstitial pneumonia, pulmonary interstitial fibrosis requiring therapy, or a history of pneumonia caused by tyrosine kinase inhibitors.

  14. Patients received radiotherapy within the past 4 weeks prior to the first first dose of study drug.

  15. Patients received therapeutic surgeries (excluding diagnosis, biopsy, or drainage procedures) within the past 4 weeks prior to the first dose of study drug, including local treatments such as radiofrequency ablation for liver metastases, or are expected to have major surgeries during the study period.

  16. Severity infection need intravenous infusion of antibiotics, antiviral drugs, or hospitalisation within the past 2 weeks prior to the first dose of study drug.

  17. Patients must use strong CYP3A4 inducers or inhibitors within the past 2 weeks prior to the first administration, or during the anticipated study period,

  18. History of severe allergy, or known allergy to any active or inactive components of the study drug product.

  19. Pregnancy or lactation.

  20. Patients with severe diseases of any organs or systems, any clinical or laboratory test abnormalities, or other reasons that investigator assess them unsuitable to participate in this clinical study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental arm 1: XS-03 + FOLFOX/FOLFIRI + Bevacizumab

Phase 1b: XS-03 escalating orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFOX or FOLFIRI and bevacizumab.

FOLFOX (85 mg/m^2 oxaliplatin, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU) , 5 mg/kg bevacizumab FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU), 5 mg/kg bevacizumab

XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

Eksperimentel: Experimental arm 2: XS-03 + FOLFOX/FOLFIRI + Bevacizumab

Phase 2: XS-03 Recommended Phase 2 Dose (RP2D) and selected one more dosage orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combinationwith FOLFOX or FOLFIRI and bevacizumab.

FOLFOX (85 mg/m^2 oxaliplatin, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU) , 5 mg/kg bevacizumab FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU), 5 mg/kg bevacizumab

XS-03 orally

Aktiv komparator: Comparator: FOLFOX/FOLFIRI + Bevacizumab

Phase 2: Comparator arm treat with FOLFOX or FOLFIRI + bevacizumab intravenously.

FOLFOX (85 mg/m^2 oxaliplatin, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU) , 5 mg/kg bevacizumab FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU), 5 mg/kg bevacizumab

Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1b: Number of participants with Dose-limiting Toxicities (DLTs) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab
Tidsramme: up to day 28

Dose-limiting toxicities were defined as events related to XS-03 that were considered an adverse reaction or suspected adverse reaction during the first cycle of treatment

up to day 28
Phase 1b: Determine the Maximum Tolerated Dose (MTD) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab
Tidsramme: up to day 28

MTD is defined as at most 1 patient out of 6 experiencing DLT

up to day 28
Phase 2: Objective Response Rate (ORR) of two experimental arms and comparator arm
Tidsramme: up to 18 months after first dose of last patient

Defined as the percentage of participants that achieve a best overall response of complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria)

up to 18 months after first dose of last patient

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Fase 1B: Mål svarprocent (ORR) for alle behandlede deltagere
Tidsramme: op til 18 måneder efter den første dosis af den sidste patient
op til 18 måneder efter den første dosis af den sidste patient
Antal deltagere med klinisk signifikant ændring fra baseline i sikkerhedsovervågning
Tidsramme: Op til 28 dage efter sidste dosis af studiemedicin
Op til 28 dage efter sidste dosis af studiemedicin
Duration of response (DOR) of all treated participants
Tidsramme: up to 18 months after first dose of last patient

Duration of response defined as time from when response was first documented until first documented disease progression or death, whichever occurs first.

up to 18 months after first dose of last patient
Progression-free survival (PFS) of treated participants
Tidsramme: up to 18 months after first dose of last patient

as determined based on RECIST version 1.1 criteria

up to 18 months after first dose of last patient
Overall survival (OS) of treated participants
Tidsramme: up to 18 months after first dose of last patient

Time in months from date of first dose for phase 1b and randomization for phase 2 to death due to any cause

up to 18 months after first dose of last patient
Number of Participants With Adverse Events (AEs) of treated participants
Tidsramme: up to 28 days after last dose of study drug

The severity of each AE will be graded using the Common Terminology Criteria for Adverse Events (CTCAE).

up to 28 days after last dose of study drug
Number of Participants With dose adjustment
Tidsramme: up to 28 days after last dose of study drug

AE associated with dose reduction, interruption and discontinuation

up to 28 days after last dose of study drug
Time to Reach Maximum Peak Plasma Concentration (Tmax)
Tidsramme: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

Pharmacokinetic parameter

From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
Maximum Plasma Concentration(Cmax)
Tidsramme: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

Pharmacokinetic parameter

From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
Area under the plasma concentration versus time curve from time zero to the last measurable concentration(AUC0-t)
Tidsramme: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

Pharmacokinetic parameter

From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
Elimination Half-life (T1/2)
Tidsramme: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

Pharmacokinetic parameter

From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
Systemic Clearance From Plasma Following Extravascular Administration (CL/F)
Tidsramme: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

Pharmacokinetic parameter

From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
The volume of distribution(Vd/F)
Tidsramme: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

Pharmacokinetic parameter

From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
Average concentration at steady state(Cavg,ss)
Tidsramme: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

Pharmacokinetic parameter

From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
Minimum observed concentration at steady state(Cmin,ss)
Tidsramme: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

Pharmacokinetic parameter

From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. maj 2025

Primær færdiggørelse (Anslået)

30. april 2028

Studieafslutning (Anslået)

30. juli 2028

Datoer for studieregistrering

Først indsendt

2. april 2025

Først indsendt, der opfyldte QC-kriterier

17. april 2025

Først opslået (Faktiske)

20. april 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner